The contribution of the WNT pathway to the therapeutic effects of montelukast in experimental murine airway inflammation induced by ovalbumin and lipopolysaccharide.

Autor: Kaya-Yasar Y; Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye., Engin S; Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye., Barut EN; Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye., Inan C; Department of Molecular Biology and Genetics, Faculty of Sciences, Karadeniz Technical University, Trabzon, Turkey., Saygin I; Department of Pathology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey., Erkoseoglu I; Department of Medical Pharmacology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey., Sezen SF; Department of Pharmacology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye.; Drug and Pharmaceutical Technology Application and Research Center, Karadeniz Technical University, Trabzon, Turkey.
Jazyk: angličtina
Zdroj: Drug development research [Drug Dev Res] 2024 Apr; Vol. 85 (2), pp. e22178.
DOI: 10.1002/ddr.22178
Abstrakt: The wingless/integrase-1 (WNT) pathway involved in the pathogenesis of inflammatory airway diseases has recently generated considerable research interest. Montelukast, a leukotriene receptor antagonist, provides therapeutic benefits in allergic asthma involving eosinophils. We aimed to investigate the role of the WNT pathway in the therapeutic actions of montelukast (MT) in a mixed type of allergic-acute airway inflammation model induced by ovalbumin (OVA) and lipopolysaccharide (LPS) in mice. Female mice were sensitized with intraperitoneal OVA-Al(OH) 3 administration in the initiation phase and intranasal OVA followed by LPS administration in the challenge phase. The mice were divided into eight groups: control, asthmatic, and control/asthmatic treated with XAV939 (inhibitor of the canonical WNT pathway), LGK-974 (inhibitor of the secretion of WNT ligands), or MT at different doses. The inhibition of the WNT pathway prevented tracheal 5-HT and bradykinin hyperreactivity, while only the inhibition of the canonical WNT pathway partially reduced 5-HT and bradykinin contractions compared to the inflammation group. Therefore, MT treatment hindered 5-HT and bradykinin hyperreactivity associated with airway inflammation. Furthermore, MT prevented the increases in the phosphorylated GSK-3β and WNT5A levels, which had been induced by airway inflammation, in a dose-dependent manner. Conversely, the MT application caused a further increase in the fibronectin levels, while there was no significant alteration in the phosphorylation of the Smad-2 levels in the isolated lungs of the mice. The MT treatment reversed the increase in the mRNA expression levels of interleukin-17A. An increase in eosinophil and neutrophil counts was observed in bronchoalveolar lavage fluid samples obtained from the mice in the inflammation group, which was hampered by the MT treatment. The inhibition of the WNT pathway did not alter inflammatory cytokine expression or cell infiltration. The WNT pathway mediated the therapeutic effects of MT due to the inhibition of GSK-3β phosphorylation as well as the reduction of WNT5A levels in a murine airway inflammation model.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: